SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-200260"
 

Search: onr:"swepub:oai:DiVA.org:liu-200260" > Injectable Biodegra...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003757naa a2200457 4500
001oai:DiVA.org:liu-200260
003SwePub
008240119s2023 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-2002602 URI
024a https://doi.org/10.1021/acs.molpharmaceut.3c006632 DOI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Mcgowan, Asmaau DelSiTech Ltd, Finland4 aut
2451 0a Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration
264 1b AMER CHEMICAL SOC,c 2023
338 a print2 rdacarrier
520 a Single-stranded antisense oligonucleotides (ASOs) are typically administered subcutaneously once per week or monthly. Less frequent dosing would have strong potential to improve patient convenience and increase adherence and thereby for some diseases result in more optimal therapeutic outcomes. Several technologies are available to provide sustained drug release via subcutaneous (SC) administration. ASOs have a high aqueous solubility and require relatively high doses, which limits the options available substantially. In the present work, we show that an innovative biodegradable, nonporous silica-based matrix provides zero-order release in vivo (rats) for at least 4 weeks for compositions with ASO loads of up to about 100 mg/mL (0.5 mL injection) without any sign of initial burst. This implies that administration beyond once monthly can be feasible. For higher drug loads, substantial burst release was observed during the first week. The concentrations of unconjugated ASO levels in the liver were found to be comparable to corresponding bolus doses. Additionally, infusion using a minipump shows a higher liver exposure than SC bolus administration at the same dose level and, in addition, clear mRNA knockdown and circulating protein reduction comparable to SC bolus dosing, hence suggesting productive liver uptake for a slow-release administration.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng
653 a oligonucleotide; long-acting injectable; silica-basedformulation; pharmacokinetics; subcutaneous
700a Gennemark, Peteru Linköpings universitet,Avdelningen för medicinsk teknik,Tekniska fakulteten,AstraZeneca, Sweden4 aut0 (Swepub:liu)petge96
700a Akieh-Pirkanniemi, Marcelineu DelSiTech Ltd, Finland4 aut
700a Wirman, Lindau DelSiTech Ltd, Finland4 aut
700a Davies, Nigelu AstraZeneca, Sweden4 aut
700a Elebring, Marieu AstraZeneca, Sweden4 aut
700a Tivesten, Annau AstraZeneca, Sweden4 aut
700a Strimfors, Marieu AstraZeneca, Sweden4 aut
700a Holtta, Mikkou AstraZeneca, Sweden4 aut
700a Soderberg, Magnusu AstraZeneca, Sweden4 aut
700a Berntsson, Veronicau AstraZeneca, Sweden4 aut
700a Balas, Danielau AstraZeneca, Sweden4 aut
700a Koskinen, Mikau DelSiTech Ltd, Finland4 aut
700a Leino, Lasseu DelSiTech Ltd, Finland4 aut
700a Abrahmsen-Alami, Susannau AstraZeneca, Sweden4 aut
710a DelSiTech Ltd, Finlandb Avdelningen för medicinsk teknik4 org
773t Molecular Pharmaceuticsd : AMER CHEMICAL SOCg 21:1, s. 143-151q 21:1<143-151x 1543-8384x 1543-8392
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-200260
8564 8u https://doi.org/10.1021/acs.molpharmaceut.3c00663

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view